Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Dynogen Draws $13.3M In Funding With In Vivo Pharmacology Work

Nov. 14, 2002

By Aaron Lorenzo

Dynogen Draws $13.3M In Funding With In Vivo Pharmacology Work

Nov. 14, 2002

By Aaron Lorenzo

NeoRx Licenses Technology To IDEC, Considers Others Actions

Nov. 14, 2002

By Aaron Lorenzo

Baxter Agrees To Acquire Epic In Deal Valued At $50M To $100M

Nov. 12, 2002

By Aaron Lorenzo

Endo, Durect Enter Potential $57M Collaboration Around Pain System

Nov. 12, 2002

By Aaron Lorenzo

Endo, Durect Enter Potential $57M Collaboration Around Pain System

Nov. 12, 2002

By Aaron Lorenzo

Baxter Agrees To Acquire Epic In Deal Valued At $50M To $100M

Nov. 12, 2002

By Aaron Lorenzo

Seattle Genetics Updates Clinical Pipeline Products

Nov. 8, 2002

By Aaron Lorenzo

Seattle Genetics Updates Clinical Pipeline Products

Nov. 8, 2002

By Aaron Lorenzo

Isis Gets Rights To ISIS 14803 Back From Elan Joint Venture

Nov. 7, 2002

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.